Business
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended Decembe
About this update from Keros Therapeutics, Inc.
[{"type":"image","alt":"Keros Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Keros Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/9bf10da51e4cb2ae9995ea0cc8482c22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_0RtSbQ0It0penXqmiH13w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9bf10da51e4cb2ae9995ea0cc8482c22","width":300,"height":106}},"lazy":false},{"type":"text","content":"LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025.","length":511,"tagName":"p"},{"type":"text","content":"“The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “With that foundation in place, our attention is firmly on execution – advancing rinvatercept into a Phase 2 clinical trial in patients with Duchenne muscular dystrophy (“DMD”) and engaging regulators on the design of a Phase 2 clinical trial in patients with amyotrophic lateral sclerosis (“ALS”). With a strong foundation in place, our focus remains on bringing potential meaningful benefit to patients and creating long-term value for our stockholders.”","length":652,"tagName":"p"},{"type":"text","content":"Recent Corporate Highlights:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Board and leadership changes:","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In February 2026, Keros announced the appointment of Charles Newton to its board of directors, effective March 9, 2026. Concurrent with Mr. Newton joining Keros’ Board of Directors, Carl Gordon, Ph.D., C.F.A., will step down as a director of the Company.","length":254,"tagName":"p"}]},{"val":[{"type":"text","content":"Esth...